SCHEMBL1496738

SCHEMBL1496738

COc1ccccc1OCC(O)CCl

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.72
CYP1A2 P05177 3/20 0.72
AGTR1 P30556 1/20 0.72
KDM4E B2RXH2 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
TSHR P16473 2/20 0.52
ALDH1A1 P00352 2/20 0.52
IDO1 P14902 1/20 0.52
HPGD P15428 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 1/20 0.51
THRB P10828 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 1/20 0.51
MAPT P10636 1/20 0.50
CASR P41180 1/20 0.49
ALOX15 P16050 1/20 0.49
PPARG P37231 1/20 0.48
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11871935 0.91 CYP1A2 (0.56) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
SCHEMBL2328960 0.89 LMNA (0.82) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
SCHEMBL29941729 0.89 LMNA (0.82) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
SCHEMBL10485650 0.86 LMNA (0.68) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
SCHEMBL14901599 0.85 CYP1A2 (0.51) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
SCHEMBL11819390 0.85 CYP1A2 (0.53) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
SCHEMBL14112094 0.84 LMNA (0.74) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
Guaifenesin SCHEMBL29759010 0.84 CYP1A2 (1.00) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
Guaifenesin SCHEMBL4322 0.84 CYP1A2 (1.00) LMNACYP1A2AGTR1KDM4ESMN1; SMN2
Guaifenesin SCHEMBL4321 0.84 CYP1A2 (1.00) LMNACYP1A2AGTR1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586774-A1 METHOD FOR PREPARATION OF RANOLAZINE Shanghai Kuoikee Laboratories Co., Ltd (CN) 2013-05-01 EP disclosed
EP-2586774-A1 METHOD FOR PREPARATION OF RANOLAZINE Shanghai Kuoikee Laboratories Co., Ltd (CN) 2013-05-01 EP disclosed
US-20130090475-A1 Process for the Preparation of Ranolazine ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) 2013-04-11 US disclosed
US-20130090475-A1 Process for the Preparation of Ranolazine ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) 2013-04-11 US disclosed
US-20130090475-A1 Process for the Preparation of Ranolazine ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) 2013-04-11 US disclosed
US-20110151258-A1 PREPARATION OF RANOLAZINE DR. REDDY'S LABORATORIES LTD. (IN) 2011-06-23 US disclosed
US-20110151258-A1 PREPARATION OF RANOLAZINE DR. REDDY'S LABORATORIES LTD. (IN) 2011-06-23 US disclosed
US-7906667-B2 Method for producing optically active alcohol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-03-15 US disclosed
US-20100234629-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-16 US disclosed
WO-2010025370-A2 PREPARATION OF RANOLAZINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-04 WO disclosed
EP-1982973-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-10-22 EP disclosed
EP-0649402-A1 PRO-DRUG CAPABLE OF RELEASING AN OXAZOLIDINONE AND, IF NEED BE, AN ACETAMIDOPHENOL UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) 1995-04-26 EP disclosed
WO-1994001395-A1 PRO-DRUG CAPABLE OF RELEASING AN OXAZOLIDINONE AND, IF NEED BE, AN ACETAMIDOPHENOL UNIVERSITE PAUL SABATIER TOULOUSE III (FR) 1994-01-20 WO disclosed
EP-0143381-B1 BIPHENYLYLALKANOIC ACID DERIVATIVES, METHODS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM Dr. L. ZAMBELETTI S.p.A. (IT) 1988-03-09 EP disclosed
US-4570013-A ANTIPYRETIC, ANALGESIC, ANTIINFLAMMATORY AGENTS; METHOXYPHENOXYPROPANOL ESTERS DR. L. ZAMBELETTI S.P.A. (IT) 1986-02-11 US disclosed
EP-0143381-A2 Biphenylylalkanoic acid derivatives, methods of preparation and pharmaceutical compositions therefrom Dr. L. ZAMBELETTI S.p.A. (IT) 1985-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090475-A1 Process for the Preparation of Ranolazine RANBP1, RANBP2, RAN LMNA 319/4885CYP1A2 21/4885AGTR1 370/4885
US-20100234629-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND ADH1A, ADH1C, ADH5 LMNA 3091/4885CYP1A2 263/4885AGTR1 604/4885
US-20110151258-A1 PREPARATION OF RANOLAZINE RANBP1, RAN, ACHE LMNA 348/4885CYP1A2 52/4885AGTR1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.